Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin for cognitive deficits in overweight euthymic adults with bipolar disorder
IRCT20251112067970N1Phase 3Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of metformin in bipolar disorder (BD) (2 arms), sponsored by Arak University of Medical Sciences. Primary endpoint: Cognitive deficits score. Started Dec 2025; status: completed.
02
Drugs
metformin
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on IRCT20251112067970N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20251112067970N1.